{"context":{"query":">>mondo>>clinical_trials","source_dataset":"mondo","target_dataset":"clinical_trials"},"stats":{"queried":1,"total":100,"mapped":1},"pagination":{"has_next":true,"next_token":"-1[]MONDO:0005086,73,MONDO:0005086,47,0]["},"schema":"id|brief_title|overall_status|phase|study_type","mappings":[{"input":"MONDO:0005086","source":"MONDO:0005086|renal cell carcinoma","targets":["NCT00414765|Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma|COMPLETED|PHASE4|INTERVENTIONAL","NCT00777504|Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors|UNKNOWN|PHASE4|INTERVENTIONAL","NCT00930345|Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma|TERMINATED|PHASE4|INTERVENTIONAL","NCT01206764|A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.|COMPLETED|PHASE4|INTERVENTIONAL","NCT01266837|Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)|COMPLETED|PHASE4|INTERVENTIONAL","NCT02056587|Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment|COMPLETED|PHASE4|INTERVENTIONAL","NCT02338570|Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE)|TERMINATED|PHASE4|INTERVENTIONAL","NCT02596035|An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma|COMPLETED|PHASE4|INTERVENTIONAL","NCT02982954|A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer|COMPLETED|PHASE4|INTERVENTIONAL","NCT05949424|OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults|UNKNOWN|PHASE4|INTERVENTIONAL","NCT07028125|Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma|RECRUITING|PHASE4|INTERVENTIONAL","NCT00033904|Survival Study Of Oncophage® vs. Observation In Patients With Kidney Cancer|COMPLETED|PHASE3|INTERVENTIONAL","NCT00126178|Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-metastatic Kidney Cancer|TERMINATED|PHASE3|INTERVENTIONAL","NCT00291369|Cytokines in Patients With Metastatic Renal Cell Carcinoma of Intermediate Prognosis|COMPLETED|PHASE3|INTERVENTIONAL","NCT00410124|RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib|COMPLETED|PHASE3|INTERVENTIONAL","NCT00420888|ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT00474786|Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib|COMPLETED|PHASE3|INTERVENTIONAL","NCT00478114|Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC)|COMPLETED|PHASE3|INTERVENTIONAL","NCT00606632|Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody|COMPLETED|PHASE3|INTERVENTIONAL","NCT00606866|MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT00631371|Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects|COMPLETED|PHASE3|INTERVENTIONAL","NCT00732914|Sequential Study to Treat Renal Cell Carcinoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT00869011|Exercise for Patients With Renal Cell Cancer Receiving Sunitinib|UNKNOWN|PHASE3|INTERVENTIONAL","NCT00930033|Clinical Trial to Assess the Importance of Nephrectomy|COMPLETED|PHASE3|INTERVENTIONAL","NCT01030783|A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT01076010|An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301).|COMPLETED|PHASE3|INTERVENTIONAL","NCT01198158|Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy|TERMINATED|PHASE3|INTERVENTIONAL","NCT01223027|Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT01224288|Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) Scramble|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT01235962|A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)|COMPLETED|PHASE3|INTERVENTIONAL","NCT01265810|Caphosol in Oral Mucositis Due to Targeted Therapy|COMPLETED|PHASE3|INTERVENTIONAL","NCT01265901|IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT01481870|Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma|UNKNOWN|PHASE3|INTERVENTIONAL","NCT01582672|Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma|TERMINATED|PHASE3|INTERVENTIONAL","NCT01613846|Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II)|COMPLETED|PHASE3|INTERVENTIONAL","NCT01762592|REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT|WITHDRAWN|PHASE3|INTERVENTIONAL","NCT01865747|A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma|COMPLETED|PHASE3|INTERVENTIONAL","NCT02030717|Randomized Study of Spinal Anesthesia Compared With Traditional Epidural Anesthesia Concerning Peroperative and Postoperative Pain After Open Nephrectomy in Patients With Renal Cell Carcinoma|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT02231749|Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)|COMPLETED|PHASE3|INTERVENTIONAL","NCT02420821|A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)|COMPLETED|PHASE3|INTERVENTIONAL","NCT02811861|Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT02829775|A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT02853331|Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)|COMPLETED|PHASE3|INTERVENTIONAL","NCT02883153|Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT03024996|A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy|TERMINATED|PHASE3|INTERVENTIONAL","NCT03055013|Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT03141177|A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT03142334|Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT03260894|Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)|COMPLETED|PHASE3|INTERVENTIONAL","NCT03288532|Renal Adjuvant MultiPle Arm Randomised Trial|RECRUITING|PHASE3|INTERVENTIONAL","NCT03408652|Efficacy and Safety of Systemic Treatments of Bone Metastases From Kidney Cancer in Patients Treated With Targeted Therapies|TERMINATED|PHASE3|INTERVENTIONAL","NCT03592472|A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)|RECRUITING|PHASE3|INTERVENTIONAL","NCT03693573|A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma|WITHDRAWN|PHASE3|INTERVENTIONAL","NCT03729245|A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)|TERMINATED|PHASE3|INTERVENTIONAL","NCT03873402|A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT03937219|Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT04510597|Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial|RECRUITING|PHASE3|INTERVENTIONAL","NCT04588246|Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery|TERMINATED|PHASE3|INTERVENTIONAL","NCT04764487|A Web-mediated Follow-up With the Web-application KidneyPRO Versus Standard Follow-up for Patients With Advanced Renal Cell Carcinoma Treated With Axitinib/Pembrolizumab in First Line|UNKNOWN|PHASE3|INTERVENTIONAL","NCT04987203|Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT05078047|Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO|RECRUITING|PHASE3|INTERVENTIONAL","NCT05219318|Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT05522231|Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)|ACTIVE_NOT_RECRUITING|PHASE2/PHASE3|INTERVENTIONAL","NCT05770037|DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers|RECRUITING|PHASE2/PHASE3|INTERVENTIONAL","NCT05796973|Measuring Oncological Value of Exercise and Statin|RECRUITING|PHASE3|INTERVENTIONAL","NCT05863351|Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT06500455|Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain|RECRUITING|PHASE3|INTERVENTIONAL","NCT06661720|Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer|RECRUITING|PHASE3|INTERVENTIONAL","NCT06726421|Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)|RECRUITING|PHASE3|INTERVENTIONAL","NCT07165418|A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI|NOT_YET_RECRUITING|PHASE3|INTERVENTIONAL","NCT07197580|Study of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC|NOT_YET_RECRUITING|PHASE3|INTERVENTIONAL","NCT07227402|A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)|RECRUITING|PHASE3|INTERVENTIONAL","NCT00001703|Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma|TERMINATED|PHASE2|INTERVENTIONAL","NCT00030992|BMS 247550 to Treat Kidney Cancer|COMPLETED|PHASE2|INTERVENTIONAL","NCT00036036|Study of CP-461 in Patients With Advanced Renal Cell Cancer|COMPLETED|PHASE2|INTERVENTIONAL","NCT00068393|Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma|COMPLETED|PHASE2|INTERVENTIONAL","NCT00081614|A Study Evaluating Tarceva in Combination With Avastin Versus Avastin Alone in Treating Metastatic Renal Cell Carcinoma|COMPLETED|PHASE2|INTERVENTIONAL","NCT00082459|Trial to Compare the Routes of Administration of an Investigational, Personalized, Therapeutic Cancer Vaccine Oncophage (HSPPC-96) in Patients With Metastatic Renal Cell Carcinoma|TERMINATED|PHASE2|INTERVENTIONAL","NCT00083109|Fluorouracil and Low-Dose Suramin as Chemosensitization in Treating Patients With Metastatic Renal Cell (Kidney) Cancer|COMPLETED|PHASE1/PHASE2|INTERVENTIONAL","NCT00087984|RNA-Loaded Dendritic Cell Cancer Vaccine|COMPLETED|PHASE1/PHASE2|INTERVENTIONAL","NCT00100685|Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC)|TERMINATED|PHASE2|INTERVENTIONAL","NCT00113217|Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma|COMPLETED|PHASE2|INTERVENTIONAL","NCT00121251|Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer|COMPLETED|PHASE1/PHASE2|INTERVENTIONAL","NCT00126490|Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer|COMPLETED|PHASE2|INTERVENTIONAL","NCT00126503|Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer|COMPLETED|PHASE1/PHASE2|INTERVENTIONAL","NCT00126594|Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer|COMPLETED|PHASE2|INTERVENTIONAL","NCT00142415|Phase I/II Dose-escalation Study of Lutetium-177-labeled cG250 in Patients With Advanced Renal Cancer|COMPLETED|PHASE1/PHASE2|INTERVENTIONAL","NCT00151645|Efficacy of Activated Lymphocytes in Renal Cell Carcinoma.|TERMINATED|PHASE2|INTERVENTIONAL","NCT00176280|Randomized Phase 2 Trial of Pre-chemotherapy Leukine vs. Leukine-Dexamethasone in Combination With Gemzar & 5-FU in Patients With Metastatic Renal Cell Carcinoma|WITHDRAWN|PHASE2|INTERVENTIONAL","NCT00197860|Dendritic Cell Based Therapy of Renal Cell Carcinoma|COMPLETED|PHASE1/PHASE2|INTERVENTIONAL","NCT00203866|Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced/Metastatic Renal Cell Carcinoma|TERMINATED|PHASE2|INTERVENTIONAL","NCT00227760|Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery|COMPLETED|PHASE2|INTERVENTIONAL","NCT00272649|Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer|COMPLETED|PHASE1/PHASE2|INTERVENTIONAL","NCT00277316|Study of XL999 in Patients With Metastatic Renal Cell Carcinoma|TERMINATED|PHASE2|INTERVENTIONAL","NCT00278395|Vorinostat in Treating Patients With Kidney Cancer|COMPLETED|PHASE2|INTERVENTIONAL","NCT00318110|Matched Unrelated Donor Transplant for Metastatic Renal Cell Carcinoma|TERMINATED|PHASE2|INTERVENTIONAL","NCT00323076|[18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours|TERMINATED|PHASE1/PHASE2|INTERVENTIONAL","NCT00330564|Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow|TERMINATED|PHASE2|INTERVENTIONAL","NCT00353301|Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma|COMPLETED|PHASE2|INTERVENTIONAL","NCT00357760|Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer|COMPLETED|PHASE2|INTERVENTIONAL"]}]}